反応式
[F:1][C:2]1[CH:11]=[C:10]2[C:5]([CH:6]=[CH:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[CH2:12][N:13]1[C:21]2[C:16](=[N:17][CH:18]=[C:19]([C:22](=O)[CH3:23])[N:20]=2)[N:15]=[N:14]1.[C:25]([NH:29][NH2:30])(=[O:28])[CH2:26][CH3:27]>>[F:1][C:2]1[CH:11]=[C:10]2[C:5]([CH:6]=[CH:7][CH:8]=[N:9]2)=[CH:4][C:3]=1[CH2:12][N:13]1[C:21]2[C:16](=[N:17][CH:18]=[C:19](/[C:22](=[N:30]/[NH:29][C:25](=[O:28])[CH2:26][CH3:27])/[CH3:23])[N:20]=2)[N:15]=[N:14]1参加物
3
実験手順
The title compound (28.5 mg, 74%) was synthesized from 1-[3-(7-fluoro-quinolin-6-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl]-ethanone (30.0 mg, 0.09 mmol) and propionic acid hydrazide (24.6 mg, 0.28 mmol) using the same procedure as described in the synthesis of example 72. 1H-NMR (400 MHz, DMSO-d6) δ ppm 10.93, 10.76 (bs, 1H), 9.45 (s, 1H), 8.92 (dd, 1H), 8.41 (d, 1H), 8.18 (d, 1H), 7.83 (d, 1H), 7.53 (dd, 1H), 6.22 (s, 2H), 2.79 (q, 2H), 2.31 (s, 3H), 1.09 (t, 3H). LCMS (method E): [MH]+=393, tR=4.78 min.
後処理
- customas described in the synthesis of example 72
出典と根拠
- ORDレコード
- ord-e23f91f19a36456a818920b614f7b186
- 出典データセット
- uspto-grants-2013_07
- 特許番号
- US08497368B2
関連ノート
読み込み中…